We distinguish standard settlements, in which the status quo is preserved, and injunctive settlements, which prohibit the defendant\u27s activity. The reverse (payment) settlement is a special type of injunctive settlement. We examine the divergence between private and social incentives to settle and policies that would minimize socially undesirable injunctive and reverse settlements (e.g., banning reverse settlements). The results are applied to competition-blocking litigation, such as patent infringement and antidumping
In Federal Trade Commission v. Actavis, Inc., the Supreme Court provided fundamental guidance about ...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
This Comment will examine how the particulars of the Hatch-Waxman Act, the regulatory scheme that go...
We distinguish standard settlements, in which the status quo is preserved, and injunctive settlement...
We distinguish standard settlements, in which the status quo is preserved, and injunctive settlement...
This paper extends the economic literature on settlement and draws some practical insights on revers...
Congratulations to Mike on a very fine book. I will confine my comments to Mike\u27s chapter on pate...
The term reverse payment has been used as shorthand to characterize a variety of diverse agreement...
One of the most pressing issues in antitrust law is how to assess settlements of patent disputes tha...
The Supreme Court’s opinion in Federal Trade Commission v. Actavis, Inc. provided fundamental guidan...
Patent settlements in which the patentee pays the alleged infringer to stay out of the market are la...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
On July 16, 2012, in In re K-Dur Antitrust Litigation, the U.S. Court of Appeals for the Third Circu...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
The current approach to “reverse payment” settlements of drug patent litigation seeks to preclude on...
In Federal Trade Commission v. Actavis, Inc., the Supreme Court provided fundamental guidance about ...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
This Comment will examine how the particulars of the Hatch-Waxman Act, the regulatory scheme that go...
We distinguish standard settlements, in which the status quo is preserved, and injunctive settlement...
We distinguish standard settlements, in which the status quo is preserved, and injunctive settlement...
This paper extends the economic literature on settlement and draws some practical insights on revers...
Congratulations to Mike on a very fine book. I will confine my comments to Mike\u27s chapter on pate...
The term reverse payment has been used as shorthand to characterize a variety of diverse agreement...
One of the most pressing issues in antitrust law is how to assess settlements of patent disputes tha...
The Supreme Court’s opinion in Federal Trade Commission v. Actavis, Inc. provided fundamental guidan...
Patent settlements in which the patentee pays the alleged infringer to stay out of the market are la...
Reverse payment settlements have ignited a firestorm debate among all affected parties: consumer gro...
On July 16, 2012, in In re K-Dur Antitrust Litigation, the U.S. Court of Appeals for the Third Circu...
Several federal courts of appeal have recently ruled on the issue of whether a pharmaceutical patent...
The current approach to “reverse payment” settlements of drug patent litigation seeks to preclude on...
In Federal Trade Commission v. Actavis, Inc., the Supreme Court provided fundamental guidance about ...
Paragraph IV of the Hatch-Waxman Act provides a mechanism for litigating pharmaceutical patent infri...
This Comment will examine how the particulars of the Hatch-Waxman Act, the regulatory scheme that go...